Taking all the above into consideration, miR-30d is shown to be modulated by YTHDC1-mediated m6A modification and there is a tumor-suppressive role of the miR-30d/RUNX1/GLUT1/HK1 axis and miR-30d/SOX4/PI3K-Akt axis in PC progression, providing a possible application of miR-30d as a diagnosis and prognosis biomarker and also a therapeutic target for PC treatment. Here, RUNX1 is linked to pachyonychia congenita.